BeOne(BeiGene) Q2 2025 Interim Financial ReportBeiGeneBeiGene reported a net profit of 450 million yuan for H1 2025, marking its first interim profit since A-share listing. Strong product sales and revised revenue and margin forecasts signal sustainable growth.
BeiGene's Q1 2025 Financial reportMarket TrendBeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
China's First! BeiGene's PD-1 Inhibitor Baizean? Approved for 14th IndicationBeiGeneBeiGene's PD-1 inhibitor Baizean? (Tislelizumab) has been approved in China for its 14th indication, marking it as the first PD-1 drug for perioperative immunotherapy in stage II-III non-small cell lung cancer. This new treatment improves event-free survival, offering hope for better outcomes.
The Various Ways of Bringing Innovative Drugs to MarketChinese Pharmaceutical MarketChinese innovative drug companies are nearing profitability, with diverse strategies like global expansion and strategic partnerships. As they release promising semi-annual reports, these companies showcase the growing potential for original innovation and sustained success in the global market.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
